Sign In
Last checked at 
23 Dec 2010 07:00
For immediate release | 23 December 2010 |
Futura Medical plc
("Futura" or "the Company")
CSD500 Progress
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, announces a year-end progress update on CSD500, the innovative condom designed to help healthy men maintain a firmer erection.
The Board considers that all outstanding points raised by the Notified Body for CSD500's CE mark have been addressed by Reckitt Benckiser and, based on recent discussions; we believe a decision is imminent. The upcoming Christmas holiday period means that the timing of the decision may be early in 2011.
For any further information please contact:
Futura Medical plc |
|
James Barder, Chief Executive | Tel: +44 (0) 1483 685 670 |
|
|
mail to: james.barder@futuramedical.com | www.futuramedical.com |
|
|
Nomura Code Securities Limited |
|
Phil Walker / Giles Balleny | Tel:+44 (0)20 7776 1200 |
|
|
For media enquiries please contact: |
|
|
|
Buchanan Communications |
|
Mark Court / Jessica Fontaine | Tel: +44 (0) 20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com
Follow the stocks
